Recent Updates on the Therapeutic Potential of HER2 Tyrosine Kinase Inhibitors for the Treatment of Breast Cancer

Author(s): Heena Singla, Anjana Munshi*, Raja Paramjit Singh Banipal, Vinod Kumar*

Journal Name: Current Cancer Drug Targets

Volume 18 , Issue 4 , 2018

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


HER2 positive breast cancer is characterized by the low survival rate in the metastatic patients. Development of resistance and disease-relapse are the major problems associated with the currently available therapies for HER2 positive breast cancer. There are two major targeted therapies for HER2 positive breast cancer viz. monoclonal antibodies and tyrosine-kinase inhibitors, and both of these therapies have their advantages and limitations. To address the limitations associated with the existing therapies, use of antibodies and TKIs as combination therapy proved to be more effective. Various chemical modifications can be performed on tyrosine-kinase inhibitors to develop novel ligands with increased selectivity for HER2 kinase. A number of tyrosine-kinase inhibitors are in various phases of clinical trials for the treatment of HER2 positive breast cancer. In the current review article, recent developments on various HER2 tyrosine-kinase inhibitors have been reported. Various structurally different scaffolds bind to the HER2 receptor and exhibit potent anti-cancer activities. The structural and pharmacophoric requirements of the scaffolds are discussed in detail so as to discover effective drug candidates for the treatment of HER2 positive breast cancer.

Keywords: Breast cancer, HER1/HER2, Tyrosine kinase inhibitors, Drug resistance, Monoclonal antibodies, Trastuzumab.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Page: [306 - 327]
Pages: 22
DOI: 10.2174/1568009617666170623122213
Price: $65

Article Metrics

PDF: 59
PRC: 1